CIGB-300 is under clinical development by Center for Genetic Engineering and Biotechnology and currently in Phase II for Cervical Cancer. According to GlobalData, Phase II drugs for Cervical Cancer have a 40% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how CIGB-300’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

CIGB-300 overview

CIGB-300 (P15-Tat) is under investigation for the treatment of adenocarcinoma of the Coronavirus disease 2019 (COVID-19), cervix, squamous cell carcinoma of the cervix, acute myeloid leukemia, and myelodysplastic syndrome and lung cancer. It is a synthetic peptide administered through intravenous and intralesional injection. It acts by targeting casein kinase 2. It was also under development for the treatment of genital warts, solid tumor and chronic lymphocytic leukemia (CLL).

Center for Genetic Engineering and Biotechnology overview

Center for Genetic Engineering and Biotechnology (CIGB) is a biotechnology company that investigates, develops, produces and markets novel biotechnological applications, therapeutic and diagnostic biopharmaceutical products, for the biomedical, agricultural and industrial sectors. CIGB is headquartered in Cuba.

For a complete picture of CIGB-300’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.